ATE117553T1 - Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren. - Google Patents
Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren.Info
- Publication number
- ATE117553T1 ATE117553T1 AT89115300T AT89115300T ATE117553T1 AT E117553 T1 ATE117553 T1 AT E117553T1 AT 89115300 T AT89115300 T AT 89115300T AT 89115300 T AT89115300 T AT 89115300T AT E117553 T1 ATE117553 T1 AT E117553T1
- Authority
- AT
- Austria
- Prior art keywords
- radiation
- dihydroisocinolinones
- analogues
- amplifiers
- substituted
- Prior art date
Links
- 230000001665 lethal effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 230000005855 radiation Effects 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000254 damaging effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23470488A | 1988-08-19 | 1988-08-19 | |
| US37275189A | 1989-07-03 | 1989-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE117553T1 true ATE117553T1 (de) | 1995-02-15 |
Family
ID=26928219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89115300T ATE117553T1 (de) | 1988-08-19 | 1989-08-18 | Substituierte dihydroisochinolinone und verwandte verbindungen als verstärker der letalen effekte von bestrahlung und bestimmten chemotherapeutika; ausgewählte verbindungen, analoga und verfahren. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0355750B1 (de) |
| JP (1) | JP2786896B2 (de) |
| AT (1) | ATE117553T1 (de) |
| CA (1) | CA1334969C (de) |
| DE (1) | DE68920798T2 (de) |
| ES (1) | ES2067508T3 (de) |
| GR (1) | GR3015850T3 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536722A (en) * | 1991-11-12 | 1996-07-16 | Pfizer Inc. | Triazine derivatives for enhancing antitumor activity |
| US5391554A (en) * | 1992-09-09 | 1995-02-21 | Warner-Lambert Company | Dihydro- and tetrahydronaphthyridines |
| US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6346536B1 (en) | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6514983B1 (en) * | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| US6395749B1 (en) | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| AU9578901A (en) * | 2000-10-30 | 2002-05-15 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| US7196085B2 (en) * | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2003255149A1 (en) | 2002-07-24 | 2004-02-09 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| CN100390164C (zh) | 2002-10-01 | 2008-05-28 | 三菱制药株式会社 | 异喹啉化合物及其医药用途 |
| CA2507027C (en) | 2002-11-22 | 2012-05-08 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
| MXPA06001274A (es) | 2003-08-01 | 2006-04-11 | Tanabe Seiyaku Co | Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio. |
| DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| CN101801371B (zh) | 2007-09-10 | 2012-11-28 | 詹森药业有限公司 | 可用作sglt抑制剂的化合物的制备方法 |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| AU2008313467B2 (en) | 2007-10-17 | 2013-08-29 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| BR122021018683B1 (pt) | 2008-10-07 | 2022-11-16 | Kudos Pharmaceuticals Limited | Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| KR101532412B1 (ko) | 2009-07-10 | 2015-06-29 | 얀센 파마슈티카 엔.브이. | 1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법 |
| SG10201500258WA (en) | 2009-10-14 | 2015-03-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
| LT2568988T (lt) | 2010-05-11 | 2016-09-12 | Janssen Pharmaceutica, N.V. | Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius |
| AU2012241897C1 (en) | 2011-04-13 | 2017-05-11 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
| TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB721286A (en) * | 1951-02-16 | 1955-01-05 | Smith Kline & French Internat | Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives |
| FR2028672A6 (de) * | 1968-03-06 | 1970-10-16 | Rhone Poulenc Sa | |
| US3674791A (en) * | 1968-03-26 | 1972-07-04 | Marion Laboratories Inc | Benzamido 2 lower alkyl decahydroisoquinolines |
| DE2143745A1 (de) * | 1971-09-01 | 1973-03-08 | Hoechst Ag | 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung |
| YU34792B (en) * | 1972-07-18 | 1980-03-15 | Pliva Pharm & Chem Works | Process for preparing phthalazone |
| AR205004A1 (es) * | 1973-10-30 | 1976-03-31 | Ishikawa M | Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona |
-
1989
- 1989-08-18 DE DE68920798T patent/DE68920798T2/de not_active Expired - Fee Related
- 1989-08-18 AT AT89115300T patent/ATE117553T1/de not_active IP Right Cessation
- 1989-08-18 ES ES89115300T patent/ES2067508T3/es not_active Expired - Lifetime
- 1989-08-18 EP EP89115300A patent/EP0355750B1/de not_active Expired - Lifetime
- 1989-08-18 JP JP1211506A patent/JP2786896B2/ja not_active Expired - Fee Related
- 1989-08-18 CA CA000608774A patent/CA1334969C/en not_active Expired - Fee Related
-
1995
- 1995-04-17 GR GR950400980T patent/GR3015850T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0355750A1 (de) | 1990-02-28 |
| DE68920798D1 (de) | 1995-03-09 |
| GR3015850T3 (en) | 1995-07-31 |
| ES2067508T3 (es) | 1995-04-01 |
| CA1334969C (en) | 1995-03-28 |
| DE68920798T2 (de) | 1995-05-18 |
| EP0355750B1 (de) | 1995-01-25 |
| JP2786896B2 (ja) | 1998-08-13 |
| JPH02124874A (ja) | 1990-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68920798D1 (de) | Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren. | |
| EE03139B1 (et) | Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon | |
| ATE73815T1 (de) | Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten. | |
| DE69122418D1 (de) | Arzneimittellösung enhaltend Derivate von FK506 | |
| LU88348I2 (fr) | Chlorhydrate d'esmolol (Brevibloc) | |
| ATE103812T1 (de) | Zusammensetzung zur behandlung von ischaemischen stoerungen in organen. | |
| MY131193A (en) | 7-(2-aminoethyl)-benzothiazolones | |
| DE3681690D1 (de) | N-substituierte 3-piperidin- oder 3-pyridincarbonsaeuren und deren derivate. | |
| ATE91625T1 (de) | Verwendung von porphyrinderivaten bei der entdeckung und behandlung von tumoren. | |
| DE3585990D1 (de) | Derivate von hydroxy- oder amino-substituierten piperidinylalkylchinazolinen. | |
| BR0010134A (pt) | Uso de derivados de ácido 2,4-diamino-3-hidroxicarboxìlico como inibidores de proteassoma | |
| DK183789D0 (da) | 2-alkyl-3-benzoylbenzofuraner og laegemidler indeholdende disse | |
| FR2681864B1 (fr) | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| ATE102195T1 (de) | Zyklische schwefelhaltige verbindungen. | |
| ATE74138T1 (de) | Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten. | |
| IL65347A0 (en) | N-substituted amido-amino acids,process for their preparation and pharmaceutical compositions comprising them | |
| DK601583A (da) | Carbamyloxybenzhydrolderivater | |
| ATE84303T1 (de) | Cysteinderivate. | |
| FI862636A0 (fi) | Farmaceutiska kompositoner med neuroleptisk effekt och foerfarande foer deras framstaellning. | |
| ATE145911T1 (de) | Inositol-phosphat-analog als kalzium- antagonistische substanz | |
| NO842345L (no) | Heksahydropyrrolo(2,1-a)isoquinolin-derivater. | |
| FI903511A0 (fi) | Pyrrolo (2,1-b) tiazolderivat. | |
| ES2000865A6 (es) | Procedimiento para la obtencion de derivados del acido 2,6-dimetil-4-(3-nitrofenil)-1,4-dihidropiridin-3,5-dicarboxilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |